Migraines are difficult to navigate, with patients often mapping their own routes to try to avoid the debilitating episodes and to deal with them when they arise. Impel NeuroPharma’s new campaign ...
NEW YORK, May 26 (Reuters) - MAP Pharmaceuticals Inc said on Tuesday its experimental orally inhaled migraine drug reached all four goals of a late-stage clinical study, and its shares more than ...
About a month after reporting positive Phase II data for drug candidates in pediatric asthma and migraine, MAP Pharmaceuticals Inc. brought in $50 million in its Series D round to move both products ...
LOS ANGELES, Sept 10 (Reuters) - An inhaled migraine drug being developed by MAP Pharmaceuticals Inc combats headache pain in a range of hard-to-treat patient groups, the company said on Thursday. MAP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results